Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

CLL

Chronic lymphocytic leukemia.

Must-know

  1. 1

    CLL14: 5-year results and MRD after venetoclax-obinutuzumab

    Al-Sawaf et al. Nature Communications. 2023.

    432 patients with previously untreated CLL were randomized. At 5 years, progression-free survival was 62.6% after venetoclax-obinutuzumab and 27.0% after chlorambucil-obinutuzumab (hazard ratio 0.35, 95% CI 0.26–0.46). MRD status at the end of therapy was associated with longer progression-free survival in both arms.

    PMID 37072421DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Accruing studies for CLL

Trials

Regulatory timeline

    CLL

    11 records

    No Hematologic updates are on file for this filter.